B. Riley Wealth Advisors Inc. Sells 544 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

B. Riley Wealth Advisors Inc. decreased its position in The Cooper Companies, Inc. (NASDAQ:COO) by 45.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 643 shares of the medical device company’s stock after selling 544 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Cooper Companies were worth $243,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Norges Bank purchased a new stake in Cooper Companies in the fourth quarter worth $196,045,000. Victory Capital Management Inc. lifted its stake in Cooper Companies by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 995,245 shares of the medical device company’s stock worth $376,641,000 after acquiring an additional 140,700 shares during the period. International Assets Investment Management LLC purchased a new stake in Cooper Companies in the fourth quarter worth $44,397,000. Ameriprise Financial Inc. lifted its position in Cooper Companies by 47.0% during the third quarter. Ameriprise Financial Inc. now owns 354,909 shares of the medical device company’s stock valued at $112,865,000 after buying an additional 113,395 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in Cooper Companies by 65.3% during the fourth quarter. Point72 Asset Management L.P. now owns 240,317 shares of the medical device company’s stock valued at $90,946,000 after buying an additional 94,906 shares during the period. Institutional investors own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Robert W. Baird raised their price objective on Cooper Companies from $116.00 to $118.00 and gave the company an “outperform” rating in a research report on Friday, May 31st. Redburn Atlantic raised Cooper Companies from a “neutral” rating to a “buy” rating and set a $125.00 price objective for the company in a research report on Tuesday, March 19th. Stifel Nicolaus reissued a “buy” rating and set a $110.00 price objective (up previously from $105.00) on shares of Cooper Companies in a research report on Friday, March 1st. Piper Sandler raised their price objective on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. Finally, TheStreet lowered Cooper Companies from a “b-” rating to a “c” rating in a research report on Thursday, February 29th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $111.42.

Cooper Companies Price Performance

NASDAQ COO opened at $87.62 on Friday. The Cooper Companies, Inc. has a one year low of $75.93 and a one year high of $104.07. The stock has a 50-day moving average of $92.79 and a 200 day moving average of $94.71. The company has a market capitalization of $17.45 billion, a price-to-earnings ratio of 51.54, a PEG ratio of 2.21 and a beta of 1.02. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.14 and a current ratio of 1.95.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, May 30th. The medical device company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.83 by $0.02. Cooper Companies had a return on equity of 8.87% and a net margin of 9.11%. The company had revenue of $942.60 million during the quarter, compared to the consensus estimate of $948.07 million. During the same period last year, the company earned $0.77 EPS. Cooper Companies’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, sell-side analysts forecast that The Cooper Companies, Inc. will post 3.57 EPS for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.